

# Life Sciences Micro-Cap Fund

Performance At: 31/03/2023

## FUND AIMS AND OBJECTIVES


Life Sciences Micro-Cap Fund (the "Fund") was launched on 01/01/2015 with the objective of attaining long-term capital growth by investment in a diversified portfolio of equity and fund instruments, principally in the Life Sciences sector/s, situated in, registered, headquartered or managed from the United States.

The Fund maintains 15 holdings as of 31/03/2023.


## Summary

<b>Start Date:</b>	01/01/2015
<b>At Date:</b>	31/03/2023
<b>Asset Value at Cost:</b>	\$899,975
<b>Total Asset Value:</b>	\$1,702,459
<b>Total Return:</b>	\$802,484
<b>Total Return:</b>	89.167%
<b>Annualised Return:</b>	17.504%

## Asset Weightings



## Performance Chart



## Assets held by the Fund

Name	Symbol	Shares	Cost	Gross Value	Unrealised Gain / (Loss)
Lineage Cell Therapeutics Inc	LCTX	15,873	60,000	22,698	-62.169%
CorMedix Inc	CRMD	31,088	60,000	131,813	119.689%
Kamada	KMDA	15,584	59,998	72,621	21.039%
Ocugen Inc	OCGN	5,469	59,995	4,594	-92.343%
ProQR Therapeutics BV	PRQR	2,761	59,997	5,356	-91.072%
Repro Med Systems Inc	KRMD	127,659	60,000	541,274	802.128%
ProPhase Labs Inc	PRPH	42,857	60,000	325,285	442.143%
Alaunos Therapeutics Inc	TCRT	11,764	59,996	7,882	-86.863%
Eyepoint Pharmaceuticals Inc	EYPT	14,388	59,998	46,042	-23.261%
Achieve Life Sciences Inc	ACHV	26,200	59,998	166,894	178.166%
Galectin Therapeutics Inc	GALT	17,492	59,998	39,532	-34.111%
Lifecore Biomedical Inc.	LFCR	4,332	59,998	16,548	-72.419%
Capricor Therapeutics Inc	CAPR	16,000	60,000	68,480	14.133%
Scynexis Inc	SCYX	6,018	59,999	18,355	-69.408%
Electromed Inc	ELMD	22,304	59,998	235,084	291.822%